An interventional study of Active transcranial direct current stimulation and Sham transcranial direct current stimulation in Ischemic Stroke and Depressive Symptoms, sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida). Completed at 1 site in Spain. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 137 studies in Ischemic Stroke with a site in Spain — 37 open to participants now, 46 under way, 7 of them phase 3. Ischemic Stroke · Spain.
Among the 137 studies in Ischemic Stroke with a site in Spain, this one is the 89th largest by enrollment of the 97 interventional ones that give a count, is one of 11 that started in 2024, is one of 48 with no phase, and was the 135th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →37 of the 137 studies in Ischemic Stroke with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18–80
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain, Belgium, Germany and 3 more countries
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18+
University of Malaga · Sites in Spain
Ages 18+
Hospital Universitario Virgen Macarena · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
137 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 21 · Phase 3 23 · Phase 4 7
First in 2000; this study’s year is marked. 11 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 240 across the 97 interventional studies, 443 across the 40 observational. Of the 78 that completed or were terminated, 23 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 137 have an industry lead sponsor. The 10 most frequent:
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
15 of the studies in Ischemic Stroke with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07361302Phase 3Boehringer IngelheimA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well | 2027-10-02 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT07793682Althaia Xarxa Assistencial Universitària de ManresaEarly Neuropsychological Rehabilitation and Family Psychoeducation After Ischemic Stroke | 2026-11-25 |
Add all 15 to your calendar (.ics) → With an account.
Among the 137 studies in Ischemic Stroke with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates a multimodal intervention pathway for affective and cognitive symptoms after ischemic stroke. Patients undergo an initial screening of depressive symptoms, cognitive function, and quality of life. Participants meeting the criteria for intervention are randomized to one of four groups: active transcranial direct current stimulation (tDCS), sham tDCS, online cognitive neurorehabilitation, or a combined intervention using active tDCS and online cognitive neurorehabilitation. Clinical outcomes include depressive symptoms, cognitive performance, and quality of life assessed longitudinally during follow-up.
Patients admitted after an acute ischaemic stroke who meet the eligibility criteria and provide written informed consent undergo an initial screening assessment including depressive symptoms, cognitive function, and perceived quality of life. Participants who meet the predefined criteria for intervention enter the randomized treatment pathway.
Participants are randomized to one of four intervention groups: active tDCS, sham tDCS, online cognitive neurorehabilitation using Guttmann NeuroPersonalTrainer (GNPT), or a multimodal intervention combining active tDCS with GNPT. Active tDCS is delivered over the dorsolateral prefrontal cortex using an anode over the left DLPFC and a cathode over the right DLPFC, at an intensity of 2 mA for 30 minutes over 14 sessions. Participants assigned to GNPT complete 32 cognitive training sessions. In the multimodal group, active tDCS is combined with GNPT during the intervention period, together with additional home-based GNPT sessions.
Participants are followed longitudinally with repeated assessments of depressive symptoms, cognitive performance, and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 14 sessions of active transcranial direct current stimulation (tDCS). Stimulation is delivered at 2 mA for 30 minutes, with the anode positioned over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the right DLPFC.
Device: Active transcranial direct current stimulation
Participants receive 14 sessions using the same electrode montage as the active tDCS group, but with sham stimulation delivered according to the study protocol
Device: Sham transcranial direct current stimulation
Participants complete 32 online cognitive neurorehabilitation sessions of 30 minutes using Guttmann NeuroPersonalTrainer (GNPT).
Behavioral: Cognitive neurorehabilitation using Guttmann NeuroPersonalTrainer
Participants receive 14 sessions of active tDCS combined with cognitive neurorehabilitation using GNPT. The remaining 18 GNPT sessions are completed at home, for a total of 32 cognitive training sessions.
Device: Active transcranial direct current stimulation · Behavioral: Cognitive neurorehabilitation using Guttmann NeuroPersonalTrainer
Active tDCS is delivered at 2 mA for 30 minutes over 14 sessions, with the anode positioned over the left dorsolateral prefrontal cortex (DLPFC) and the cathode over the right DLPFC.
Sham tDCS is delivered over 14 sessions using the same electrode montage as active tDCS, without therapeutic current stimulation.
Participants complete 32 cognitive neurorehabilitation sessions of approximately 30 minutes each using Guttmann NeuroPersonalTrainer (GNPT). In the multimodal group, 14 GNPT sessions are performed concurrently with active tDCS and the remaining 18 sessions are completed at home.
Change in depressive symptoms measured with the 17-item Hamilton Depression Rating Scale (HDRS-17)
Depressive symptoms are assessed using the 17-item Hamilton Depression Rating Scale (HDRS-17) at the pre-intervention assessment (T1), 3 months post-randomization (T2), and 6 months post-randomization (T3). Total scores range from 0 to 52, with higher scores indicating greater severity of depressive symptoms. In this study, a score ≥7 was considered indicative of affective impairment.
Time frame: From initial screening through the 6-month follow-up period
Change in cognitive composite z-score
Cognitive performance is assessed at the pre-intervention assessment (T1), 3 months post-randomization (T2), and 6 months post-randomization (T3). Raw neuropsychological test scores are converted into scaled scores using standardized population-based norms and subsequently transformed into z-scores. Domain-specific cognitive scores are calculated by averaging the z-scores of tests assigned to each cognitive domain. The global cognitive composite is calculated as the average z-score across all individual tests included in the neuropsychological battery. The composite z-score has no fixed minimum or maximum value; a score of 0 represents the normative mean and one z-score unit represents one standard deviation. Higher scores indicate better cognitive performance.
Time frame: From randomization through the 6-month follow-up
Change in perceived quality of life measured with the ECVI-38
Perceived quality of life is assessed using the Stroke-Specific Quality of Life Scale (ECVI-38) at the pre-intervention assessment (T1), 3 months post-randomization (T2), and 6 months post-randomization (T3). The ECVI-38 is a 38-item stroke-specific measure. Each item is scored from 1 to 5, yielding a total score ranging from 38 to 190. Higher scores indicate poorer health-related quality of life.
Time frame: From randomization through the 6-month follow-up
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2024 to primary completion in Apr 2026, 24 months.
Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's 24 months is below that.
Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)